THTX · Theratechnologies Inc.

-

Please sign in to comment on THTX

1 Comment

Admin

3 years, 7 months ago

Theratechnologies Inc is currently in a long term uptrend where the price is trading 30.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.

Theratechnologies Inc's total revenue rose by 16.6% to $19M since the same quarter in the previous year.

Its net income has increased by 14.0% to $-6M since the same quarter in the previous year.

Finally, its free cash flow fell by 757.7% to $-6M since the same quarter in the previous year.

Based on the above factors, Theratechnologies Inc gets an overall score of 4/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	CA88338H1001
Industry	Drug Manufacturers-Specialty & Generic
Sector	Healthcare

Target Price	4.6
PE Ratio	None
Market Cap	199M
Dividend Yield	0.0%
Beta	1.48

ABOUT

Theratechnologies Inc.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

THTX · Theratechnologies Inc.

-

Theratechnologies Inc.

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Theratechnologies Inc. using a moving average strategy